CorMedix Inc. — Director's Dealing 2013

Mar 22, 2013

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CorMedix Inc. (CRMD)
CIK: 0001410098
Period of Report: 2013-03-20

Reporting Person: Cohen Richard (Director, Chief Financial Officder)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2013-03-20	Stock Option (right to buy)	$0.9	A	40000	Acquired	2023-03-20	Common Stock, $0.001 par value per share (40000)	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to buy)	$0.68	2022-12-05	Common Stock, $0.001 par value per share (70000)	70000	Direct
Stock Option (right to buy)	$2.1	2021-01-14	Common Stock, $0.001 par value per share (30000)	30000	Direct
Stock Option (right to buy)	$3.125	2020-03-30	Common Stock, $0.001 par value per share (20000)	20000	Direct

Footnotes

F1: The options vest quarterly over two years beginning on June 30, 2013.

F2: These options vest as follows: Fifty percent (50%) on the date of issuance of the CE Mark certification for Neutrolin in Europe, if the CE Mark approval is obtained on or before June 30, 2013, and (b) fifty percent (50%) on December 31, 2013.

F3: These options vest on January 14, 2012.

F4: These options vest as follows: 1/3 on March 30, 2010; an additional 1/3 on March 30, 2011; and the remaining 1/3 on March 30, 2012.